Jazz Pharmaceuticals, Inc.

NASDAQ: JAZZ
$140.15
-$3.98 (-2.8%)
Closing price September 17, 2020
Monday's top analyst upgrades and downgrades included Adobe, BP, FedEx, GameStop, Gilead Sciences, Kroger, MGM Resorts, Micron Technology, Nvidia and Tradeweb Markets.
Thursday's top analyst upgrades, downgrades and initiations included Akamai Technologies, Anheuser-Busch InBev, Boeing, BP, Comcast, Duke Energy, Gap, Kinder Morgan, Lyft, Occidental Petroleum, Snap,...
Friday's top analyst upgrades, downgrades and initiations included Amazon.com, Amgen, Coca-Cola, Danaher, Electronic Arts, IBM, Proofpoint, Sprint, UPS, Uber, Vertex Pharmaceuticals and Visa.
Monday's top analyst upgrades, downgrades and initiations included ADT, Altria, Biogen, Charles Schwab, Chewy, Deere, Dollar Tree, eBay, Intel, Nike, Kroger, Peloton, Roku and Wells Fargo.
Monday's top analyst upgrades, downgrades and initiations included Amarin, Bank of America, Citigroup, JPMorgan, Liberty SiriusXM, Microsoft, Tesla, TripAdvisor, Twitter and Workday.
Merrill Lynch research shows significant potential for upside for these stocks when the ISM manufacturing indicators rise, which signs suggest they may do in 2020.
Here are three biotech stocks that recently saw their 50-day moving average cross above the 200-day average, a golden cross, plus two that went the other way.
The top analyst upgrades, downgrades and initiations for Wednesday included Baidu, BP, Ciena, Chevron, Cree, Exxon Mobile, Home Depot, Medtronic, Nvidia and Urban Outfitters.
The top analyst upgrades, downgrades and initiations on Tuesday included Agilent Technologies, Allergan, Beyond Meat, Canopy Growth, Dollar Tree, Facebook, Luckin Coffee, Lyft, Mylan, Symantec,...
Stocks were indicated up strong by almost 1% on Wednesday morning for the Dow Jones industrial average, S&P 500 and Nasdaq, quite similar to Tuesday’s gap-up open. This follows last...
24/7 Wall St. takes a look at what is coming up in the FDA calendar regarding biotech and pharmaceutical companies expecting updates to their drug pipeline or other major events for the rest of 2018.
The top analyst upgrades, downgrades and other research calls from Wednesday include AECOM, CyberArk, Dillard's, Hasbro, Mattel, Newell, Papa John's, Shopify, Snap and Tesla.
The top analyst upgrades, downgrades and other research calls from Wednesday include AT&T, Comcast, Hess, Netflix, Petrobras, Sirius XM, Texas Instruments, Verizon and Walt Disney.
There is deep value for long-term investors in these specialty pharmaceutical companies, and the ability to buy in to some of the best companies in the industry at rock bottom pricing.
Monday’s top analyst upgrades, downgrades and initiations include AstraZeneca, Dr Pepper Snapple, Fortinet, GrubHub, Jazz Pharmaceutical and Unilever.